Press release
Crossject announces its financial calendar 2018
Dijon, 1st March 2018
CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations, announces its projected financial calendar 2018.
Financial calendar 2018
* After trading
Contacts :
| Crossject Patrick Alexandre info@crossject.com | Investor contact CM-CIC Market Solutions Catherine Couanau +33 (0) 1 53 48 81 97 catherine.couanau@cmcic.fr |
| Press contact Buzz & Compagnie Mélanie Voisard +33 (0)3 80 43 54 89 melanie.voisard@buzzetcompagnie.com Audrey Lachat +33 (0)3 80 43 54 89 audrey.lachat@buzzetcompagnie.com |
About CROSSJECT · www.crossject.com
Crossject (ISIN: FR0011716265; Ticker: ALCJ) is a specialty pharma company developing a portfolio of drugs for use in emergency situations (severe migraines, epilepsy, temporary paralysis, anaphylactic shock, overdoses, acute asthma attacks, etc.). With Zeneo®, its patented needle-free injection system, Crossject provides an efficient response to emergencies by enabling the simple self-administration of drugs. Crossject has been listed on the Euronext Growth market since February 2014.
Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.